The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Alexion Pharmaceuticals Inc

Nasdaq: ALXN
Last

(U.S.) $197.15

Today's change0.00 0.00%
Updated August 4 4:00 PM EDT. Delayed by at least 15 minutes.
 

Alexion Pharmaceuticals Inc

Nasdaq: ALXN
Last

(U.S.) $197.15

Today's change0.00 0.00%
Updated August 4 4:00 PM EDT. Delayed by at least 15 minutes.

Alexion Pharmaceuticals Inc closed at (U.S.)$197.15.

Shares have lost 3.14% over the last five days, but have gained 6.55% over the last year to date. This security has outperformed the S&P 500 by 16.14% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $197.15
  • High--
  • Low--
  • Bid / Ask(U.S.) $33.33 / (U.S.) $0.00
  • YTD % change+6.55%
  • Volume0
  • Average volume (10-day)1,579,330
  • Average volume (1-month)1,599,790
  • Average volume (3-month)2,260,176
  • 52-week range(U.S.) $150.06 to (U.S.) $208.88
  • Beta0.62
  • Trailing P/E67.37×
  • P/E 1 year forward40.70×
  • Forward PEG2.42×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $2.93
Updated August 4 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+24.78%

Based on its net profit margin of 24.78%, Alexion Pharmaceuticals Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.00%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue636600599555
Total other revenue--------
Total revenue636600599555
Gross profit584531550503
Total cost of revenue52694952
Total operating expense455497396318
Selling / general / administrative221187184158
Research & development13221612597
Depreciation / amortization--543
Interest expense (income), net operating--------
Unusual expense (income)5019338
Other operating expenses, total--------
Operating income181104204237
Interest income (expense), net non-operating---1-1--
Gain (loss) on sale of assets--------
Other--------
Income before tax177107205236
Income after tax17091153178
Income tax, total7165258
Net income17091153178
Total adjustments to net income--------
Net income before extra. items17091153178
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items17091153178
Inc. avail. to common incl. extra. items17091153178
Diluted net income17091153178
Dilution adjustment0----0
Diluted weighted average shares205202202201
Diluted EPS excluding extraordinary itemsvalue per share0.830.450.760.88
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share1.070.530.880.91